全文获取类型
收费全文 | 428篇 |
免费 | 26篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 3篇 |
基础医学 | 36篇 |
口腔科学 | 6篇 |
临床医学 | 29篇 |
内科学 | 123篇 |
皮肤病学 | 2篇 |
神经病学 | 5篇 |
特种医学 | 88篇 |
外科学 | 32篇 |
综合类 | 23篇 |
预防医学 | 22篇 |
眼科学 | 10篇 |
药学 | 24篇 |
中国医学 | 5篇 |
肿瘤学 | 44篇 |
出版年
2022年 | 3篇 |
2021年 | 2篇 |
2020年 | 4篇 |
2019年 | 2篇 |
2018年 | 5篇 |
2017年 | 1篇 |
2016年 | 6篇 |
2015年 | 6篇 |
2014年 | 13篇 |
2013年 | 18篇 |
2012年 | 17篇 |
2011年 | 30篇 |
2010年 | 16篇 |
2009年 | 26篇 |
2008年 | 22篇 |
2007年 | 20篇 |
2006年 | 12篇 |
2005年 | 8篇 |
2004年 | 12篇 |
2003年 | 9篇 |
2002年 | 9篇 |
2001年 | 12篇 |
2000年 | 5篇 |
1999年 | 10篇 |
1998年 | 17篇 |
1997年 | 17篇 |
1996年 | 18篇 |
1995年 | 14篇 |
1994年 | 8篇 |
1993年 | 12篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 6篇 |
1989年 | 10篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有458条查询结果,搜索用时 17 毫秒
61.
62.
Gastric angiodysplasia 总被引:1,自引:0,他引:1
63.
WE Gillies FRACO FRACS FRCS Anne MV Brooks MD PhD FRACO FRACS FRACP 《Clinical & experimental ophthalmology》1992,20(3):239-242
A method of combined cataract extraction with posterior chamber intraocular lens and trabeculectomy using separate incisions was tested in 44 operations on 38 patients. The mean preoperative intraocular pressure (IOP) of 28.1 ± 11.7 (range 12 to 56) mmHg on maximum medication was lowered to 13.9 ± 3.4 (9 to 23) mmHg at one year, with half the eyes still requiring topical medication. The IOP was 40 mmHg or more preoperatively in eight eyes and 20 mmHg or more in only two patients at one year. There were no rises in IOP above 20 mmHg in the early postoperative period (days 1 and 2). Visual acuity was 6/9 or better in 27 and 6/12 in three eyes. There was an expulsive haemorrhage in one case, rupture of the posterior capsule in two eyes and a choroidal detachment in one eye, but no flat anterior chambers. The two-incision method allowed placement of an intraocular lens with good postoperative pressure control. 相似文献
64.
65.
Nash RA; Pineiro LA; Storb R; Deeg HJ; Fitzsimmons WE; Furlong T; Hansen JA; Gooley T; Maher RM; Martin P; McSweeney PA; Sullivan KM; Anasetti C; Fay JW 《Blood》1996,88(9):3634-3641
The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus- host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Phase II study conducted at two centers. Forty-three patients, 15 to 54 (median 41) years of age, were transplanted for hematologic malignancies. Thirty-seven of 43 evaluable patients had evidence of sustained marrow engraftment. Five patients died before day 17 after transplantation. The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (range, 14 to 30) days. Nephrotoxicity (serum creatinine concentration > 2 mg/dL or doubling of baseline) occurred in 32 patients (74% cumulative incidence during the first 100 days after transplant). Other adverse effects included hypertension (n = 27), hyperglycemia (n = 27), neurotoxicity (n = 9) and thrombotic thrombocytopenic purpura (n = 2). Severe veno- occlusive disease of the liver occurred in 9 (21%) of the 43 patients. Eighteen patients (42%) developed grades II to IV acute GVHD and five (12%) developed grades III to IV acute GVHD. Twelve of 25 evaluable patients developed extensive chronic GVHD within 1 year of marrow transplantation resulting in an estimate of the probability of developing this complication of 48%. The cumulative incidence of transplant-related mortality during the first 100 days was 37%. Kaplan- Meier estimates of disease-free survival at 2 years for good-risk, poor- risk, and all patients were 65%, 4%, and 32%, respectively. FK506 in combination with a short course of MTX appears active in preventing acute GVHD after marrow transplantation from unrelated donors. Further studies comparing the combination of FK506 and MTX with cyclosporine and MTX for the prevention of acute GVHD are warranted. 相似文献
66.
Percutaneous transluminal angioplasty: the treatment of choice for renovascular hypertension due to fibromuscular dysplasia 总被引:2,自引:0,他引:2
Tegtmeyer CJ; Elson J; Glass TA; Ayers CR; Chevalier RL; Wellons HA Jr; Studdard WE Jr 《Radiology》1982,143(3):631-637
Twenty-three renal artery stenoses in 21 hypertensive patients, caused by fibromuscular dysplasia, were treated with percutaneous transluminal angioplasty (PTA). Follow-up over a period of 1 to 30 months, including angiography, renal vein renin assay, and radionuclide flow studies, was performed in 8 patients, each with one stenosis. Dilatation was initially successful in all cases and was successfully repeated in 1 case. The mean systolic pressure decreased by 61.81 mm Hg and the mean diastolic pressure by 36.28 mm Hg in response to treatment. Thirteen patients were cured, 8 were felt to have better control of blood pressure on medication, and there was no failures. This study demonstrates that PTA is a clinically effective method of treating renovascular hypertension due to fibromuscular dysplasia. 相似文献
67.
68.
69.
Swords R Nolan A Fay M Quinn J O'Donnell R Murphy PT 《Clinical and laboratory haematology》2006,28(1):57-59
A patient with cold-type autoimmune haemolytic anaemia for 8 years developed progressive B cell chronic lymphocytic leukaemia (CLL). Despite the risk of fludarabine induced exacerbation of haemolysis, he was given aggressive anti-CLL therapy with six courses of FCR (fludarabine 25 mg/m2 D1-3, cyclophosphamide 250 mg/m2 D2-4 and rituximab 375 mg/m2 D1) every 4 weeks. This resulted in a marked acute increase in haemolysis shortly after completing each course of fludarabine. However, haemolysis had settled to its baseline level by the time of subsequent courses of FCR. FCR resulted in complete clinical remission of CLL but residual haemolysis persisted. The patient was then given four weekly infusions of single agent rituximab, resulting in ongoing remission of haemolysis. In this patient, rituximab appears to have controlled fludarabine induced exacerbation of autoimmune haemolysis. In addition, subsequent single agent rituximab therapy resulted in prolonged remission of cold-type autoimmune haemolytic anaemia. It remains to be seen if the addition of rituximab will allow other patients with a positive direct Coomb's test and/or autoimmune haemolysis to receive fludarabine containing chemotherapy without undue risk of life-threatening haemolytic anaemia. 相似文献
70.